Giuliano Fratta - COSCIENS Biopharma Senior CFO
| CSCI Stock | 3.13 0.04 1.29% |
CFO
Giuliano Fratta is Senior CFO of COSCIENS Biopharma
| Address | 222 Bay Street, Toronto, ON, Canada, M5K 1E7 |
| Web | https://www.cosciensbio.com |
COSCIENS Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.2334) % which means that it has lost $0.2334 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6592) %, meaning that it created substantial loss on money invested by shareholders. COSCIENS Biopharma's management efficiency ratios could be used to measure how well COSCIENS Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of now, COSCIENS Biopharma's Total Assets are increasing as compared to previous years. The COSCIENS Biopharma's current Total Current Assets is estimated to increase to about 15.6 M, while Non Current Assets Total are projected to decrease to under 14.5 M.Similar Executives
| Found 1 records | CFO Age | ||
| Nathaniel CPA | MGIC Investment Corp | 40 | |
Management Performance
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.23 |
COSCIENS Biopharma Leadership Team
Elected by the shareholders, the COSCIENS Biopharma's board of directors comprises two types of representatives: COSCIENS Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of COSCIENS. The board's role is to monitor COSCIENS Biopharma's management team and ensure that shareholders' interests are well served. COSCIENS Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, COSCIENS Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| ICDD MBA, CEO President | ||
| Giuliano Fratta, Senior CFO | ||
| Matthias Gerlach, Senior Production | ||
| Nicola MD, Chief Development | ||
| Michael Teifel, Senior Officer |
COSCIENS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is COSCIENS Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (1.61) % | ||||
| Current Valuation | (13.04 M) | ||||
| Shares Outstanding | 3.12 M | ||||
| Shares Owned By Insiders | 1.32 % | ||||
| Shares Owned By Institutions | 6.69 % | ||||
| Number Of Shares Shorted | 1.34 K | ||||
| Price To Book | 0.49 X | ||||
| Price To Sales | 2.66 X |
Currently Active Assets on Macroaxis
When determining whether COSCIENS Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of COSCIENS Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cosciens Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cosciens Biopharma Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in COSCIENS Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of COSCIENS Biopharma. If investors know COSCIENS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.69) | Revenue Per Share 3.759 | Quarterly Revenue Growth 0.041 | Return On Assets (0.23) | Return On Equity (0.66) |
The market value of COSCIENS Biopharma is measured differently than its book value, which is the value of COSCIENS that is recorded on the company's balance sheet. Investors also form their own opinion of COSCIENS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is COSCIENS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because COSCIENS Biopharma's market value can be influenced by many factors that don't directly affect COSCIENS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between COSCIENS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if COSCIENS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, COSCIENS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.